Table 3.
Crude and Adjusted Odds of Receiving Chemotherapy by Patient and Clinicopathologic Characteristics: Analysis on 82,592 Patients Diagnosed From 2004 to 2016
| Variable | Univariate |
Multivariate |
||||
|---|---|---|---|---|---|---|
| OR (95% CI), p | ||||||
| Age, y | ||||||
| 40 to <65 | Ref | Ref | ||||
| 65 to <75 | 0.76 | (0.71–0.80) | <0.0001 | 0.72 | (0.67–0.78) | <0.0001 |
| 75 to <80 | 0.54 | (0.50–0.58) | <0.0001 | 0.52 | (0.47–0.57) | <0.0001 |
| ≥80 | 0.31 | (0.29-0.34) | <0.0001 | 0.30 | (0.27–0.33) | <0.0001 |
| Sex | ||||||
| Male | Ref | Ref | ||||
| Female | 1.00 | (0.95–1.05) | 0.856 | 0.98 | (0.93–1.04) | 0.510 |
| Race | ||||||
| White | Ref | Ref | ||||
| Black | 0.80 | (0.73–0.87) | <0.0001 | 0.85 | (0.77–0.93) | 0.0004 |
| Other | 0.82 | (0.68–0.98) | 0.032 | 0.87 | (0.72–1.04) | 0.126 |
| Hispanic origin | ||||||
| Non-Hispanic | Ref | Ref | ||||
| Hispanic | 1.00 | (0.84–1.18) | 0.960 | 1.09 | (0.92–1.29) | 0.335 |
| Insurance status | ||||||
| Private | Ref | Ref | ||||
| Medicare | 0.59 | (0.56–0.63) | <0.0001 | 0.87 | (0.80–0.94) | 0.0004 |
| Medicaid | 0.74 | (0.67–0.82) | <0.0001 | 0.72 | (0.65–0.80) | <0.0001 |
| Other government insurance | 0.39 | (0.33–0.45) | <0.0001 | 0.41 | (0.35–0.48) | <0.0001 |
| Uninsured | 0.61 | (0.54–0.69) | <0.0001 | 0.59 | (0.52–0.66) | <0.0001 |
| Median household income, $ | ||||||
| <30,000 | Ref | Ref | ||||
| 30,000–34,999 | 1.06 | (0.98–1.15) | 0.150 | 0.97 | (0.89–1.06) | 0.465 |
| 35,000–45,999 | 1.09 | (1.01–1.18) | 0.025 | 0.93 | (0.85–1.02) | 0.143 |
| ≥46,000 | 1.11 | (1.03–1.20) | 0.005 | 0.90 | (0.81–1.00) | 0.041 |
| Education (% with no HS degree) | ||||||
| ≥29 | Ref | Ref | ||||
| 20–28.9 | 1.20 | (1.11–1.29) | <0.0001 | 1.22 | (1.12–1.32) | <0.0001 |
| 14–19.9 | 1.19 | (1.11–1.28) | <0.0001 | 1.26 | (1.15–1.38) | <0.0001 |
| <14 | 1.26 | (1.17–1.36) | <0.0001 | 1.40 | (1.27–1.55) | <0.0001 |
| Year of diagnosis | ||||||
| 2004–2006 | Ref | Ref | ||||
| 2007–2009 | 1.25 | (1.16–1.35) | <0.0001 | 1.26 | (1.17–1.37) | <0.0001 |
| 2010–2012 | 1.46 | (1.36–1.58) | <0.0001 | 1.49 | (1.38–1.61) | <0.0001 |
| 2013–2016 | 1.47 | (1.37–1.58) | <0.0001 | 1.50 | (1.40–1.61) | <0.0001 |
| CCS | ||||||
| 0 | Ref | Ref | ||||
| 1 | 1.00 | (0.94–1.06) | 0.976 | 1.03 | (0.98–1.10) | 0.263 |
| ≥2 | 0.85 | (0.79–0.91) | <0.0001 | 0.90 | (0.84–0.97) | 0.003 |
| Facility type | ||||||
| CP | Ref | Ref | ||||
| Comprehensive CP | 1.02 | (0.95–1.11) | 0.564 | 1.03 | (0.95–1.12) | 0.451 |
| Academic and research program | 1.00 | (0.92–1.09) | 0.933 | 0.97 | (0.89–1.06) | 0.551 |
| Integrated Network Cancer Program | 0.96 | (0.87–1.06) | 0.429 | 0.95 | (0.86–1.05) | 0.286 |
| Treatment at >1 facility | ||||||
| No | Ref | Ref | ||||
| Yes | 1.20 | (1.10–1.31) | <0.0001 | 1.15 | (1.05–1.25) | 0.003 |
CCS, Charlson-Deyo Comorbidity Score; CI, confidence interval; CP, community program; HS, high school; Ref, referent.